Review finds greater heart risk in anti-smoking drug Chantix

07/5/2011 | Reuters

A meta-analysis in the Canadian Medical Association Journal found that healthy, middle-age users of Chantix, Pfizer's smoking-cessation drug, had a 72% greater risk of heart problems requiring hospitalization compared with placebo users. Last month, the FDA said Chantix's warning label will be revised to mention increased cardiovascular risk in those with a history of heart disease. Pfizer is working with the agency "to conduct a combined analysis of clinical-trial data" that "will help further evaluate the cardiovascular safety of Chantix," the company said.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC